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Background: Three prospective studies have evaluated the association between dietary acrylamide intake and endometrial
cancer (EC) risk with inconsistent results. The objective of this study was to evaluate the association between acrylamide intake and
EC risk: for overall EC, for type-I EC, and in never smokers and never users of oral contraceptives (OCs). Smoking is a source of
acrylamide, and OC use is a protective factor for EC risk.
Methods: Cox regression was used to estimate hazard ratios (HRs) for the association between acrylamide intake and EC risk in
the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Acrylamide intake was estimated from the EU
acrylamide monitoring database, which was matched with EPIC questionnaire-based food consumption data. Acrylamide intake
was energy adjusted using the residual method.
Results: No associations were observed between acrylamide intake and overall EC (n¼ 1382) or type-I EC risk (n¼ 627). We
observed increasing relative risks for type-I EC with increasing acrylamide intake among women who both never smoked and were
non-users of OCs (HRQ5vsQ1: 1.97, 95% CI: 1.08–3.62; likelihood ratio test (LRT) P-value: 0.01, n¼ 203).
Conclusions: Dietary intake of acrylamide was not associated with overall or type-I EC risk; however, positive associations with
type I were observed in women who were both non-users of OCs and never smokers.
Acrylamide is a known neurotoxin in humans, and a carcinogen in
animals (Friedman, 2003; LoPachin and Gavin, 2008; Hogervorst
et al, 2010). In 1994, based on animals studies, as well as evidence
found in humans, the International Agency for Research on Cancer
(IARC) classified acrylamide as ‘probably carcinogenic’ to humans
(IARC group 2A; IARC, 1994). In 2002, Swedish researchers
discovered acrylamide in some heat-treated carbohydrate-rich
foods (Tareke et al, 2002), and further research concluded that
acrylamide is formed during common cooking procedures
(predominantly through the Maillard reaction), such as frying,
grilling, and baking (Friedman, 2003). In the European Prospective
Investigation into Cancer and Nutrition (EPIC) cohort, the main
determinants of estimated dietary intake of acrylamide based on
24-h dietary recall (DR) were bread, crisp bread, rusks, coffee, fried
potatoes, cakes, biscuits, and cookies (Freisling et al, 2013).
Acrylamide is also a component of cigarette smoke, thus, smoking
is an important source of exposure (Boettcher et al, 2005; Vesper
et al, 2008).
Acrylamide is metabolised via the Cyp2e1 enzyme system to
glycidamide, a chemically reactive epoxide and mutagen in animals
(Doroshyenko et al, 2009; Hogervorst et al, 2010). After acrylamide
administration, hormone-related (including uterine tumours) and
other tumours (e.g., oral tissues) have been observed in rats
(Johnson et al, 1986).
Endometrial cancer (EC) is the fourth most common cancer
diagnosed in European women, but mortality is relatively low with
a 5-year survival rate varying from 65 to 85% (Cook et al, 2006;
Ferlay et al, 2013). There is considerable international variation in
incidence as well as mortality, and both rates increase dramatically
with age (Cook et al, 2006; Ferlay et al, 2013; Jamison et al, 2013).
Established risks factors for EC are obesity, low physical activity,
history of polycystic ovary syndrome, and greater lifetime exposure
to estrogens (Kaaks et al, 2002; Cook et al, 2006). The use of oral
contraceptives (OCs, containing both oestrogen and progestin in
the formula) is well established to lower the risk of developing EC
(Cook et al, 2006; Gierisch et al, 2013). There is evidence that
tobacco smoking also reduces the risk of EC (Terry et al, 2004;
Cook et al, 2006); however, an EPIC study reported an increased
risk of EC in premenopausal women who smoked (Al-Zoughool
et al, 2007). Endometrial cancer is generally classified into two
types: type-I EC are mostly endometrioid adenocarcinomas and are
associated with unopposed oestrogen exposure; and type-II EC
tumours are mainly serous carcinomas, are believed to be
oestrogen independent, and have poor prognosis (Amant et al,
2005; Setiawan et al, 2013).
Three prospective epidemiological studies have assessed the
relationship between dietary intake of acrylamide and EC risk. The
Netherlands Cohort Study (NLCS) observed a positive association
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between acrylamide intake and EC risk, especially in never smokers
(Hogervorst et al, 2007). Likewise, the Nurses’ Health Study (NHS)
reported an increased relative risk among women with the highest
acrylamide intake (Wilson et al, 2010); however, no associations
between acrylamide intake and EC were observed in the Swedish
Mammography Cohort (SMC; Larsson et al, 2009).
The present study evaluated the association between ques-
tionnaire-based dietary intake of acrylamide and the risk of overall
EC (type I, type II, and undefined) and type-I EC tumours, using
data from 301 113 EPIC cohort participants. Subgroup analyses
among never-smoking women and never users of OCs were
performed with the aim to eliminate the influence of smoking
(both a source of acrylamide and a protective factor) and the
protective effect of OCs on EC risk.
METHODS
Study population. The EPIC study was initiated between 1992
and 1998 in 23 centres from 10 European countries with the aim to
investigate the relationships between nutrition and lifestyle factors,
and cancer and other chronic diseases. All participants gave written
informed consent. Ethical review boards from the IARC and local
centres participating in EPIC approved the study. The EPIC
methodology has been reported in detail by Riboli et al (2002).
The EPIC study includes 521 330 participants, of which 367 903
are women. A total of 66 790 women were excluded from the
current analyses because they were diagnosed with cancer before
recruitment (n¼ 19 853), had a hysterectomy (n¼ 35 116), had
incomplete follow-up data (n¼ 2896), had no lifestyle or dietary
information (n¼ 2877), and no information on dietary intake of
acrylamide at baseline (n¼ 3), or had an extreme ratio of energy
intake to energy required (n¼ 6045); resulting in 301 113
participants for this analysis.
Identification of endometrial cancer cases. Information on
cancer incidence was obtained through population cancer
registries, or via a combination of methods: health insurance
records, cancer and pathology registries, and active follow-up
(France, Germany, Naples, and Greece). Subjects were followed
until cancer diagnosis (except non-melanoma skin cancer),
emigration, death, or until the end of follow-up (dates varied
between centres, from December 2004 to June 2010).
Tumour morphology was specified for 664 (48%) cases, of
which 627 (93%) were classified as type I (endometrioid
adenocarcinomas), and 37 (7%) as type II (serous, or clear cell,
or squamous adenocarcinomas; Tavassoli and Devilee, 2003).
Overall EC comprises type I, type II, and cases that were undefined
for histology. Tumours were classified as C54 according to the
International Classification of Diseases, 10th revision.
Dietary and acrylamide intake assessment. Information on diet
was assessed at baseline (with timeframe referring to the previous
12 months) through country-specific, validated dietary question-
naires (DQ; Riboli et al, 2002). The development of the acrylamide
database in EPIC has been previously described (Freisling et al,
2013; Obon-Santacana et al, 2013). To summarise, the EPIC
acrylamide database is a compilation of the information acquired
to a large extent from the European Community Institute for
Reference Materials and Measurements (IRMM). The average
acrylamide levels for specific foods in the IRMM database were
obtained through a combination of methods based on either liquid
or gas chromatography coupled to mass spectrometry. All food
items with acrylamide data derived from the IRMM database were
classified according to EPIC-Soft food classification (Voss et al,
1998; Slimani et al, 2000). The reported foods on the DQ and,
when available, their relevant description (e.g., baked potatoes)
were matched with the corresponding foods in the acrylamide
database. Information on cooking methods for acrylamide sources
was available for potatoes (except in Italy), bread, and breaded
meats. If an exact match was not possible, the food was linked to
the mean of all foods of the respective food group in the acrylamide
database (Freisling et al, 2013; Obon-Santacana et al, 2013).
Lifestyle and reproductive information assessment. At baseline,
questionnaires were used to collect data on tobacco smoking,
education, physical activity, and menstrual and reproductive factors
(i.e., age at first menstrual period, ever use of OCs, ever use of
hormone replacement therapy (HRT)). Baseline menopausal status
was self-reported for each woman in most centres, and in case of
incomplete data, an algorithm was developed based on the age at
recruitment: women were classified as premenopausal if their baseline
ages were o46 years, or reported having menstrual cycles the year
before recruitment; perimenopausal if their ages were between 46 and
55 years, or had irregular menses the year before recruitment; and
postmenopausal if their ages were 456 years, or had bilateral
ovariectomy (surgical menopause), or hado4 menstrual cycles in the
past year before recruitment (Riboli et al, 2002).
Height, weight, and waist or hip circumference were measured
at baseline by trained personnel for all EPIC participants, except
for most participants in France, Norway and Oxford cohorts,
where height and weight were self-reported. Umeå and Norway did
not record data on waist or hip circumference, and only some
participants from France have information on waist (29%) and hip
circumference (29%; Riboli et al, 2002).
Statistical analysis. Proportional hazards models (Cox regression)
were used to estimate hazards ratio (HR) and 95% confidence
intervals (95% CI) for overall EC risk in relation to dietary intake
of acrylamide. Analyses were also performed separately for risk of
type-I EC. Analyses for type-II EC cases were not carried out due
to small sample sizes (n¼ 37). All multivariate models had age as
the time scale and were stratified by study centre to control for
centre effects (i.e., questionnaire design and follow-up procedures),
and by age at recruitment (in 1-year categories) as the primary
time variable.
All estimates of acrylamide intake in these analyses were energy
adjusted using the residual method (Willett, 1998; Ferrari et al,
2013). One continuous variable and one categorical variable for
dietary intake of acrylamide were evaluated in Cox models: average
daily intake in 10 mg increments (10 mg per day), and quintiles of
intake (mg per day) based on the distribution in the full EPIC
cohort of women.
The following variables were included as known risk factors or
potential confounders in these analyses: body mass index (BMI,
kgm 2), smoking status (never smokers, current pipe or cigar or
occasional smokers, current cigarette smokers: 1–15, 16–25, or
X26 cigarettes per day, former cigarette smokers who quit 420
years, 11–20 years, or p10 years before recruitment), history of
diabetes (no, yes), OC use (never, ever), HRT use (never, ever),
baseline menopause status combined with age at menopause
(premenopausal, perimenopausal, postmenopausal with: o45,
45–49, 50–52, 53–55, and X56 years, surgical menopause,
postmenopausal women with missing age at menopause), parity
(nulliparous, 1, 2, X3, parous but with missing number of full-
term pregnancies), and age at menarche (o12, 12, 13, 14, andX15
years). Variables for education level (none, primary, technical/
professional, secondary, and higher education), physical activity
using the Cambridge index (Wareham et al, 2003), alcohol intake
(non-drinkers, drinkers of 0–6, 46–12, 412–24, and 424 g per
day), total fat (g per day), total fibre (g per day), vegetables (g per
day), and fruits, nuts and seeds consumption (g per day) were
evaluated, but were not included in final models because they did
not change effect estimates 410%. Missing values for specific
variables were categorised as ‘unknown’ and were included in the
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analyses. All statistical models presented in this study were further
adjusted for total energy intake (per 1000 kcal per day).
Analyses of effect-measure modification were carried out by
known EC risk factors (BMI, menopausal status, and HRT use),
by known protective factors (OC use, and smoking status), by
geographical region, and by factors that may affect the activity of
Cyp2e1 (alcohol intake, and BMI; Wilson et al, 2009; Freisling et al,
2013). The following subgroups were examined: BMI
(o25 kgm 2, X25 kgm 2), OC use (never, ever), HRT use
(never, ever), baseline menopausal status (premenopausal, peri-
menopausal, and postmenopausal), smoking status (never, current,
or former smokers), and alcohol intake (never, ever drinkers). For
region-specific analyses, countries were classified as northern
(France, UK, The Netherlands, Germany, Sweden, Denmark, and
Norway) and southern (Italy, Spain, and Greece); and by median
acrylamide-intake level (‘high’ X21 mg per day and ‘low’ o21 mg
per day) in the EPIC cohort.
Sensitivity analyses were additionally performed excluding all
cases diagnosed during the first 2 years of follow-up, with the aim
to avoid possible influences of preclinical disease on dietary habits
including intakes of acrylamide.
To evaluate dose-response trends, the median value for each
acrylamide quintile was estimated and included in a score test.
Statistical significance of effect-measure modification was evaluated
using a LRT and based on the continuous acrylamide intake variable.
The proportional hazards (PHs) assumption was tested in STATA
(College Station, Texas, USA) using Schoenfeld residuals (Schoenfeld,
1982), and it was met for type-I EC analyses; however, it was violated
for overall EC analyses. Variables responsible for the PH violation were:
OC use, HRT use, and smoking status; thus, stratified analyses by these
variables were also performed for overall EC risk, and the PH
assumption was subsequently met. All analyses were performed using
SAS v. 9.1 (Cary, NC, USA).
RESULTS
Basic information on cohorts members. The average acrylamide
intake in the EPIC subcohort of women was 24±13 mg per day
(0.4±0.2 mg per kg body weight per day), and the 10th–90th
percentile range was 10–41 mg per day (0.2–0.6 mg per kg body
weight per day). Denmark, followed by the UK and The
Netherlands, had the highest mean and median dietary acrylamide
intakes, while Italy had the lowest acrylamide intake (Table 1). In
total, after 11 years of follow-up there were 1382 first primary EC
cases, of which 627 were classified as type-I EC, 37 type-II EC, and
718 cases that were not specified with regard to histology (Table 1).
Women with the highest acrylamide-intake levels tended to
have the highest intakes of energy, total fats, total carbohydrates,
vegetables, and coffee. Women with the highest intake levels
tended to be premenopausal, have a higher proportion of OC use
and with longer duration, and were more often current smokers or
former smokers at baseline (Table 2). In contrast, women classified
in the lower quintiles tended to be postmenopausal, non-
consumers of alcohol and tobacco, and to have lower levels of
physical activity (Table 2). There were few differences across
acrylamide intake quintiles by age, age at first menstrual period,
age at menopause, BMI, or waist-to-hip ratio (Table 2).
Overall EC risk and type-I EC risk. No association was observed
between acrylamide intake and overall EC (Table 3) or type-I EC
risk (Table 4). Similar results were found when we restricted the
analyses to cases diagnosed 2 years after recruitment (Tables 3 and
4), or when known type-I and type-II EC were combined in the
same analysis (data not shown). Further, an analysis among EC
cases that could not be classified into type-I or type-II EC was also
carried out, but no associations were observed (data not shown).
Most of the stratified analyses performed with overall EC (type I,
type II, and undefined) cases indicated no heterogeneity between
subgroups (Table 3). When stratified analyses by OC use, and by
OC use and smoking were performed, statistically significant LRT
P-values were observed; however, neither the continuous nor the
categorical acrylamide variable suggested an association with
disease risk (Table 3).
Effect-measure modification by OC use and smoking in type-I
EC. Subgroup analyses for known type-I EC were also stratified by
smoking status, OC use, menopausal status, HRT use, BMI, and
geographical region. None of the HRs in never smokers or ever
Table 1. Estimated dietary intake of acrylamide and EC cases by country in the EPIC subcohort of women
Country
Cohort
sample
Person-
years
EC
cases
N (%)
Type-I
cases
N (%)
Type-II
cases
N (%)
Cases
undefined
by type
N (%)
Acrylamide
(lg per day)
Mean±s.d.
Acrylamidea
(lg per day)
Mean±s.d.
Acrylamide (lg per kg
body weight per day)
Mean±s.d.
France 60 702 629 899 276 (20.0) 79 (12.6) 3 (8.1) 194 (27.0) 20.4±8.8 18.3±6.6 0.4±0.2
Italy 27 760 310 816 132 (9.6) 48 (7.7) 1 (2.7) 83 (11.6) 10.9±6.1 8.8±5.7 0.2±0.1
Spain 22 783 275 042 102 (7.4) 48 (7.7) 3 (8.1) 51 (7.1) 20.6±12.1 21.3±10.3 0.3±0.2
United
Kingdom
46 068 513 816 170 (12.3) 74 (11.8) 5 (13.5) 91 (12.7) 33.1±15.3 33.4±13.1 0.5±0.3
The
Netherlands
22 140 260 499 107 (7.7) 59 (9.4) 5 (13.5) 43 (6.0) 31.2±13.7 31.7±12.1 0.5±0.2
Greece 13 967 136 097 18 (1.3) 4 (0.6) 1 (2.7) 13 (1.8) 19.2±9.1 19.8±7.2 0.3±0.1
Germany 23 321 231 579 82 (5.9) 67 (10.7) 4 (10.8) 11 (1.5) 24.5±11.2 25.3±9.7 0.4±0.2
Sweden 26 375 349 308 183 (13.2) 1 (0.2) 4 (10.8) 178 (24.8) 22.4±9.7 23.6±8.2 0.3±0.2
Denmark 24 473 269 910 182 (13.2) 140 (22.3) 9 (24.3) 33 (4.6) 35.6±11.7 35.5±10.2 0.5±0.2
Norway 33 524 326 296 130 (9.4) 107 (17.1) 2 (5.4) 21 (2.9) 17.9±6.5 20.6±5.8 0.3±0.1
Total 301 113 3303 262 1382 627 37 718 23.7±13.0 23.7±12.0 0.4±0.2
Abbreviations: EC¼ endometrial cancer; EPIC¼European Prospective Investigation into Cancer and Nutrition; s.d.¼ standard deviation.
aEnergy adjusted using the residual method.
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Table 2. Estimated total dietary intake of acrylamide (energy adjusted using the residual method) and covariates at baseline used in the analyses: EPIC
subcohort (301 113 women)
Energy-adjusted acrylamide intake (lg per day)
p14.5 14.6–19.5 19.6–24.2 24.3–32.0 32.1–222.4
Participants (n) 60 222 60 223 60223 60223 60222
Endometrial cancer cases (n) 277 271 298 250 286
Type-I EC cases (n) 105 111 125 122 164
Energy-adjusted acrylamide intake (median; mg per day) 10.7 17.2 21.7 27.4 39.3
Age (years) 51.1±8.4a 50.8±9.1 50.1±9.6 49.7±10.6 49.6±11.5
Age at first menstrual period (years)b 12.8±1.5 13.1±1.5 13.1±1.5 13.2±1.5 13.2±1.6
Age at menopause (years)b 49.3±4.4 49.3±4.5 49.3±4.5 49.4±4.4 49.4±4.3
Menopausal status (%)
Premenopausal 36.5 35.76 37.8 40.05 40.15
Perimenopausal 18.16 20.55 19.68 16.51 12.92
Postmenopausalc 45.34 43.69 42.52 43.44 46.93
Ever use of OCs (%)
Yes 49.45 55.8 58.12 61.46 65.48
Unknown 0.65 2.51 4.53 4.04 1.8
Duration of using OCs (years)b 6.1±6.6 7.4±7.2 7.9±7.4 8.4±7.5 8.7±7.5
Ever use of HRT (%)
Yes 19.96 22.71 21.94 21.29 22.22
Unknown 3.25 6.69 9.09 9.33 6.37
Duration of using HRT (years)b 2.9±3.1 3.4±3.3 3.6±3.6 3.9±4.2 4.2±4.6
Smoking status (%)
Never 59.49 60.01 55.53 52.35 49.68
Former 19.45 20.8 22.71 23.88 25.15
Current 18.86 15.75 18.88 21.61 23.85
Unknown 2.2 3.44 2.88 2.16 1.31
Cigarettes per day (smokers only) 13.1±8.7 12.5±7.7 12.8±7.5 13.2±7.6 14.0±7.8
Time since quittingd (years) 13.7±9.0 15.0±9.6 14.8±9.8 14.9±10.1 14.9±10.5
Prevalent diabetes (%)
Yes 2.67 2.42 2.0 1.65 1.61
Unknown 1.94 4.42 5.07 4.59 4.64
Alcohol
Non-consumers (%) 22.56 19.08 16.49 13.51 10.24
Consumers (g per day) 9.2±14.1 7.2±10.9 6.6±10.1 7.6±10.8 8.5±10.9
Education (%)
Primary school completed 31.48 20.23 21.76 21.93 21.13
Higher educatione 22.57 25.92 23.91 23.56 21.5
Unknown 1.72 2.69 2.98 4.3 6.31
Physical activity (%)
Inactive 28.99 21.35 19.13 18.26 17.44
Active 9.49 9.71 11.78 15.93 22.08
Unknown 7.09 18.22 19.71 12.13 4.29
BMI (kgm 2) 25.1±4.5 24.6±4.4 24.7±4.3 24.8±4.4 25.0±4.4
WHRb 0.8±0.1 0.8±0.1 0.8±0.1 0.8±0.1 0.8±0.1
Energy (kcal) 2098.2±571.9 1860.1±521.1 1810.3±515.9 1873.8±516.2 2027.5±523.3
Total fats (g per day) 84.8±28.3 74.5±26.3 70.9±25.8 72.6±25.9 78.3±26.4
Carbohydrates (g per day) 224.5±74.2 203.7±63.6 204±62.3 213.0±63.9 232.7±67.3
Vegetables (g per day) 252.9±165.6 232.3±146.5 203.1±133.6 198.8±129.8 204.5±127.7
Coffee (ml per day) 123.6±129.9 228.5±194.4 337.8±240.2 441.8±305.9 643.4±449.3
Bread, crisp bread, and rusks (g per day) 121.1±76.0 114.9±65.9 115.7±66.1 116.6±67.4 124.2±69.1
Potatoes (g per day) 48.6±46.2 70.8±52.9 84.3±57.5 95.1±64.4 105.7±67.5
Cakes and biscuits (g per day) 34.8±37.6 34.8±33.4 38.4±34.3 42.4±38.6 48.3±47.7
Abbreviations: BMI¼body mass index; EC¼ endometrial cancer; EPIC¼European Prospective Investigation into Cancer and Nutrition; HRT¼hormonal replacement therapy; OCs¼oral
contraceptives; WHR¼waist-to-hip ratio.
aMean±s.d.
bNumber of women missing the following; age at first menstrual period: 10 321; age at menopause: 201 651; duration of using OCs: 142 462; duration of using HRT: 278 012; number of
cigarettes: 243 668; time since quitting smoking; 236 217; and WHR: 88 717.
cIncludes surgical menopause.
dOnly in former smokers.
eHigher education includes any university degree or above.
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Table 3. Hazard ratios and 95% confidence intervals for the estimated dietary intake of acrylamide (energy-adjusted using the residual method) and EC
risk in EPIC
Energy-adjusted acrylamide intake (lg per day)
Quintiles
10 lg
increments Q1 (p14.5) Q2 (14.6–19.5) Q3 (19.6–24.2) Q4 (24.3–32.0) Q5 (32.1–222.4)
Trend test
P-value LRTP-valuea
Final model – overall EC
N cases 1382 277 271 298 250 286
HR (95% CI)b 0.98 (0.92–1.05) 1.00 (ref) 1.05 (0.86–1.29) 1.11 (0.90–1.36) 0.88 (0.71–1.10) 0.98 (0.78–1.25) 0.53
Cases diagnosed X2 years after recruitment
N cases 1186 240 217 268 215 246
HR (95% CI)b 0.98 (0.91–1.05) 1.00 (ref) 0.97 (0.78–1.20) 1.12 (0.89–1.39) 0.85 (0.67–1.08) 0.95 (0.74–1.23) 0.52
Overall EC – stratified analyses
Smoking status
Never smokers
N cases 747 147 142 153 132 173
HR (95% CI)c 0.97 (0.89–1.05) 1.00 (ref) 1.03 (0.79–1.34) 1.04 (0.79–1.36) 0.82 (0.61–1.10) 1.01 (0.75–1.38) 0.90
Ever smokersd 0.20
N cases 587 123 118 135 110 101
HR (95% CI)c 0.98 (0.89–1.08) 1.00 (ref) 1.08 (0.80–1.45) 1.23 (0.91–1.66) 0.96 (0.69–1.33) 0.86 (0.60–1.24) 0.23
OC use
Non-OC users
N cases 800 180 155 165 127 173
HR (95% CI)e 1.03 (0.94–1.12) 1.00 (ref) 1.07 (0.83–1.38) 1.09 (0.84–1.42) 0.83 (0.62–1.11) 1.17 (0.86–1.58) 0.51
OC users 0.03
N cases 547 94 111 121 117 104
HR (95% CI)e 0.92 (0.83–1.02) 1.00 (ref) 1.05 (0.76–1.46) 1.16 (0.83–1.61) 0.97 (0.68–1.39) 0.79 (0.53–1.15) 0.08
Smoking status combined with OC use
Never smokers and
non-OC users
N cases 477 106 90 94 75 112
HR (95% CI)f 1.02 (0.92–1.13) 1.00 (ref) 1.05 (0.76–1.44) 1.08 (0.77–1.50) 0.82 (0.57–1.18) 1.28 (0.88–1.85) 0.24
Ever smokersd and non-
OC users
N cases 299 68 58 68 47 58
HR (95% CI)f 1.02 (0.89–1.17) 1.00 (ref) 1.09 (0.73–1.65) 1.28 (0.84–1.95) 0.87 (0.55–1.39) 0.98 (0.60–1.60) 0.65
Never smokers and OC
users
0.04
N cases 253 39 49 52 54 59
HR (95% CI)f 0.89 (0.77–1.03) 1.00 (ref) 1.03 (0.64–1.67) 0.98 (0.60–1.61) 0.83 (0.50–1.40) 0.73 (0.42–1.26) 0.13
Ever smokersd and OC
users
N cases 277 54 58 63 60 42
HR (95% CI)f 0.93 (0.80–1.08) 1.00 (ref) 1.10 (0.71–1.69) 1.22 (0.78–1.90) 1.07 (0.67–1.71) 0.76 (0.44–1.30) 0.22
Alcohol intake
Never drinkers
N cases 253 70 59 38 35 51
HR (95% CI)b 1.06 (0.91–1.24) 1.00 (ref) 0.95 (0.62–1.46) 0.72 (0.44–1.18) 0.59 (0.35–1.00) 1.03 (0.60–1.76) 0.76
Ever drinkers 0.07
N cases 1129 207 212 260 215 235
HR (95% CI)b 0.97 (0.90–1.04) 1.00 (ref) 1.10 (0.87–1.39) 1.27 (1.00–1.61) 0.96 (0.75–1.24) 1.01 (0.77–1.32) 0.54
Body mass index
o25 kgm 2
N cases
HR (95% CI)g 1.01 (0.91–1.12) 1.00 (ref) 0.94 (0.70–1.27) 1.13 (0.83–1.53) 0.92 (0.67–1.28) 0.93 (0.64–1.35) 0.68
X25 kgm 2 0.96
N cases
HR (95% CI)g 0.99 (0.90–1.08) 1.00 (ref) 1.29 (0.96–1.73) 1.21 (0.89–1.64) 0.94 (0.68–1.31) 1.12 (0.79–1.57) 0.89
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smokers indicated associations between dietary acrylamide intake
and type-I EC risk; however, statistically significant evidence for
heterogeneity was observed (LRT P-value: 0.01; Table 4).
Inverse associations were observed for the highest versus the
lowest quintile of acrylamide intake (HRQ5vsQ1: 0.57, 95% CI:
0.34–0.96; P-value for trend: 0.01), as well as a continuous variable
(HR: 0.83, 95% CI: 0.71–0.95; Table 4). Regarding the HRs obtained
in the subgroup of non-OC users, none of them were statistically
significant (HR10 mg per day: 1.10, 95% CI: 0.99–1.23; Table 4).
Moreover, the OC-use model was additionally adjusted by
duration of OC use (per 2 years of OC use), and the results were
similar to those presented without adjustment for this variable
(data not shown).
There were some differences in non-dietary variables between
OC users and non-users. OC users with the highest acrylamide
intake tended to have a higher proportion of former or current
smokers, and these women tended to smoke more cigarettes per
day than non-users. Further, non-OC users were older than OC
users, but with similar age at menopause. With regard to dietary
factors, there were no major differences between OC users and
non-users (data not shown).
The association between acrylamide intake and type-I EC risk
among OC users and non-users was also evaluated by smoking
status. Women who at baseline reported being never smokers
and non-users of OCs (including 203 type-I EC cases) were
at the highest risk of developing type-I EC, when acrylamide
was evaluated both as a continuous variable and in quintiles
(HR10 mg per day: 1.17, 95% CI: 1.02–1.34; HRQ5vsQ1: 1.97, 95% CI:
1.08–3.62; P-value for trend: 0.01; Table 4). Otherwise, associations
between dietary acrylamide intake and type-I EC were below the
null value in ever smokers (current and former smokers) and OC
users (HR10 mg per day: 0.75, 95% CI: 0.60–0.94; Table 4). The LRT
P-value of the contrast between ‘never smokers/non-OC users’,
‘ever smokers/non-OC users’, ‘never smokers/OC users’, and ‘ever
smokers/OC users’ for the continuous acrylamide intake variable
was 0.01 (Table 4).
Other effect-measure modifications in type-I EC. There was no
evidence for effect-measure modification by BMI (Table 4), HRT
use, or by geographical region (all LRT P-values 40.12, data not
shown); however, evidence for effect-measure modification was
found when the analyses were stratified by baseline menopausal
status (LRT P-value: 0.01; Table 4), but none of the individual HRs
were statistically significant. Likewise, effect-measure modification
was observed by alcohol intake (LRT P-value: 0.01), but only the
continuous variable in never drinkers showed a statistically
significant positive association (HR10 mg per day: 1.23, 95% CI:
1.02–1.47; Table 4).
DISCUSSION
No overall association was observed between dietary intake of
acrylamide and overall EC or type-I EC risk; nevertheless, elevated
relative risks, as well as P-values for linear trend were observed for
the association between dietary intake of acrylamide and type-I EC
among women who both never smoked and never used OCs.
Statistically significant inverse associations between type-I EC risk
and acrylamide intake were observed in OC users, and among OC
users and ever smokers.
It is widely published that use of OCs (containing oestrogen
and progestin) is protective against EC risk, and this effect is
Table 3. ( Continued )
Energy-adjusted acrylamide intake (lg per day)
Quintiles
10 lg
increments Q1 (p14.5) Q2 (14.6–19.5) Q3 (19.6–24.2) Q4 (24.3–32.0) Q5 (32.1–222.4)
Trend test
P-value LRTP-valuea
Menopausal status
Premenopausal
N cases 253 67 54 52 45 35
HR (95% CI)h 0.88 (0.74–1.04) 1.00 (ref) 1.12 (0.72–1.74) 1.12 (0.70–1.78) 1.00 (0.61–1.64) 0.68 (0.37–1.22) 0.17
Perimenopausal 0.05
N cases 268 51 56 73 44 44
HR (95% CI)h 1.05 (0.89–1.23) 1.00 (ref) 1.08 (0.69–1.70) 1.29 (0.82–2.04) 0.83 (0.50–1.39) 1.18 (0.67–2.10) 0.90
Postmenopausali
N cases 861 159 161 173 161 207
HR (95% CI)h 1.01 (0.93–1.10) 1.00 (ref) 1.05 (0.80–1.38) 1.06 (0.80–1.40) 0.84 (0.62–1.13) 1.03 (0.76–1.40) 0.99
Abbreviations: BMI¼body mass index; CI¼ confidence interval; EC¼ endometrial cancer; EPIC¼European Prospective Investigation into Cancer and Nutrition; HR¼ hazards ratio;
HRT¼ hormonal replacement therapy; LRT¼ likelihood ratio test; OCs¼oral contraceptives.
aAll LRT P-values for effect measure modification are based on the continuous acrylamide intake variable (per 10mg per day).
bStratified by age at recruitment, centre, smoking status, OC use, and HRT use. Adjusted for total energy intake (per 1000 kcal per day), BMI, prevalent diabetes, menopause status combined
with age at menopause, parity, and age at menarche.
cStratified by age at recruitment, centre, OC use, and HRT use. Adjusted for total energy intake (per 1000 kcal per day), BMI, prevalent diabetes, menopause status combined with age at
menopause, parity, and age at menarche.
dEver smokers: former and current smokers.
eStratified by age at recruitment, centre, smoking status, and HRT use. Adjusted for total energy intake (per 1000 kcal per day), BMI, prevalent diabetes, menopause status combined with age at
menopause, parity and age at menarche.
fStratified by age at recruitment, centre, and HRT use. Adjusted for total energy intake (per 1000 kcal per day), BMI, prevalent diabetes, menopause status combined with age at menopause,
parity, and age at menarche.
gStratified by age at recruitment, centre, smoking status, OC use, and HRT use. Adjusted for total energy intake (per 1000 kcal per day), prevalent diabetes, menopause status combined with
age at menopause, parity, and age at menarche.
hStratified by age at recruitment, centre, smoking status, OC use, and HRT use. Adjusted for total energy intake (per 1000 kcal per day), BMI, prevalent diabetes, parity, and age at menarche.
iIncludes surgical menopause.
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Table 4. Hazard ratios and 95% confidence intervals for the estimated dietary intake of acrylamide (energy-adjusted using the residual method) and
type-I endometrial cancer risk in EPIC
Energy-adjusted acrylamide intake (lg per day)
Quintiles
10 lg
increments Q1 (p14.5) Q2 (14.6–19.5) Q3 (19.6–24.2) Q4 (24.3–32.0) Q5 (32.1–222.4)
Trend test
P-value LRTP-valuea
Final model – Type I
N cases 627 105 111 125 122 164
HR (95% CI)b 0.98 (0.90–1.07) 1.00 (ref) 1.00 (0.74–1.35) 1.04 (0.77–1.42) 0.87 (0.63–1.21) 0.97 (0.69–1.36) 0.79
Cases diagnosed X2 years after recruitment
N cases 556 98 93 117 107 141
HR (95% CI)b 0.96 (0.87–1.06) 1.00 (ref) 0.89 (0.65–1.23) 1.04 (0.76–1.43) 0.84 (0.60–1.19) 0.93 (0.65–1.32) 0.75
Type I – stratified analyses
Smoking status
Never smokers
N cases 350 56 54 67 69 104
HR (95% CI)c 1.06 (0.95–1.19) 1.00 (ref) 0.97 (0.63–1.48) 1.14 (0.74–1.74) 0.97 (0.62–1.51) 1.25 (0.79–1.98) 0.21
Ever smokersd 0.01
N cases 257 44 51 55 50 57
HR (95% CI)c 0.90 (0.78–1.03) 1.00 (ref) 1.02 (0.64–1.63) 1.00 (0.62–1.62) 0.80 (0.48–1.34) 0.70 (0.41–1.19) 0.09
OC use
Non-OC users
N cases 347 65 56 65 58 103
HR (95% CI)e 1.10 (0.99–1.23) 1.00 (ref) 0.96 (0.64–1.45) 1.09 (0.71–1.67) 0.90 (0.57–1.42) 1.40 (0.89–2.22) 0.06
OC users 0.01
N cases 273 39 54 59 63 58
HR (95% CI)e 0.83 (0.71–0.95) 1.00 (ref) 0.97 (0.62–1.51) 0.93 (0.59–1.47) 0.79 (0.49–1.28) 0.57 (0.34–0.96) 0.01
Smoking status combined with OC use
Never smokers and
non-OC users
N cases 203 35 29 36 35 68
HR (95% CI)f 1.17 (1.02–1.34) 1.00 (ref) 1.03 (0.58–1.81) 1.28 (0.72–2.27) 1.12 (0.61–2.06) 1.97 (1.08–3.62) 0.01
Ever smokersd and
non-OC users
N cases 134 26 25 27 21 35
HR (95% CI)f 1.04 (0.86–1.26) 1.00 (ref) 0.99 (0.51–1.91) 0.99 (0.50–1.98) 0.76 (0.36–1.62) 1.01 (0.47–2.19) 0.98
Never smokers and
OC users
0.01
N cases 145 20 25 31 33 36
HR (95% CI)f 0.89 (0.73–1.09) 1.00 (ref) 0.76 (0.40–1.45) 0.83 (0.44–1.59) 0.68 (0.35–1.35) 0.59 (0.29–1.21) 0.17
Ever smokersd and OC
users
N cases 120 18 25 27 29 21
HR (95% CI)f 0.75 (0.60–0.94) 1.00 (ref) 1.02 (0.52–1.99) 1.00 (0.50–1.98) 0.84 (0.41–1.72) 0.45 (0.20–1.00) 0.02
Alcohol intake
Never drinkers
N cases 103 28 19 13 17 26
HR (95% CI)b 1.23 (1.02–1.47) 1.00 (ref) 0.76 (0.40–1.44) 0.61 (0.29–1.28) 0.93 (0.46–1.89) 1.77 (0.86–3.64) 0.07
Ever drinkers 0.01
N cases 524 77 92 112 105 138
HR (95% CI)b 0.93 (0.85–1.03) 1.00 (ref) 1.09 (0.77–1.54) 1.19 (0.83–1.69) 0.90 (0.61–1.31) 0.91 (0.62–1.35) 0.30
Body mass index
o25 kgm 2
N cases 256 43 48 62 53 50
HR (95% CI)g 0.86 (0.74–1.00) 1.00 (ref) 0.88 (0.56–1.38) 1.11 (0.71–1.73) 0.78 (0.48–1.27) 0.56 (0.33–0.96) 0.02
X25 kgm 2 0.28
N cases 371 62 63 63 69 114
HR (95% CI)g 1.06 (0.95–1.18) 1.00 (ref) 1.12 (0.75–1.69) 0.99 (0.64–1.52) 0.92 (0.59–1.44) 1.34 (0.85–2.10) 0.12
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maintained for years (Amant et al, 2005; Cook et al, 2006; Cibula
et al, 2010; Gierisch et al, 2013). Likewise, cigarette smoking tends
to lower the risk of developing EC, and it is thought to be more
pronounced in recent smokers (Cook et al, 2006). All the relative
risk estimates for type-I EC risk observed among OC users and
ever smokers were below the null value; however, because OC use,
duration of OC use, and smoking are associated with higher
acrylamide intake in EPIC, and are also associated with lower EC
risk, residual confounding by these variables may play a role in the
observed inverse associations (in OC users and smokers). In
addition, OC users, compared to non-OC users, tended to smoke
more cigarettes per day and reported less time since having quit
smoking. Thus, these baseline characteristics may have partially
influenced the results obtained in this subgroup of women.
Moreover, it has been hypothesised that acrylamide may have
hormonal effects, and the results in non-OC users for type I are
potentially compatible with this hypothesis, since type-I EC is
considered to be oestrogen driven (Amant et al, 2005); never-
theless, this hypothesis has not been substantiated, and other
mechanisms (i.e., genotoxicity caused by glycidamide) may be
compatible with the results (Hogervorst et al, 2010, 2013).
The relation between dietary intake of acrylamide and EC risk
has been previously published in three prospective cohort studies.
Both the NLCS and NHS studies found statistically significantly
increased relative risks: the NLCS among never-smoking women,
and the NHS in the entire cohort (Hogervorst et al, 2007; Wilson
et al, 2010). Although the NLCS and NHS studies did not evaluate
the association between acrylamide intake and type-I EC
specifically, about 80% of EC cases are thought to be type-I
endometrioid tumours (Amant et al, 2005); thus, the majority of
the cases in the previous publications were likely type-I EC cases.
Only the SMC study observed no associations between acrylamide
intake and EC risk (Larsson et al, 2009), and this could be due to
the smaller baseline ranges of acrylamide intake in that study. The
median acrylamide intake for the reference group in the SMC was
16.9 mg per day, and for the highest intake category was 32.5 mg per
day, whereas in EPIC, the median for the reference group was
9.3 mg per day, and for the highest intake category was 44.0 mg per
day. All three previous studies presented statistical models adjusted
for OC use, but none reported analyses stratified by OC use.
Some evidence for an inverse association between the highest
and lowest acrylamide quintiles and type-I EC risk was observed
among women with a BMI o25 kgm 2; however, neither the
continuous variable for acrylamide intake (per 10 mg per day) nor
the LRT P-value were statistically significant. A suggestive
increased risk for type-I EC was observed in women who
reported never drinking alcohol at baseline when the continuous
acrylamide variable was evaluated; nevertheless, this result was
based on 103 type-I EC cases. Further, suggestive evidence for
heterogeneity of the association between dietary acrylamide intake
and type-I EC risk was also indicated by smoking status, and by
menopausal status at baseline; nevertheless no dose-response trend
was observed.
The strengths of our study are that EPIC is one of the largest
prospective cohort studies on diet and cancer, and recall bias is
unlikely because exposure and diet information were collected
years before cancer diagnoses. The present study had more cases
than the other three previously published studies (n¼ 1382), and
this allowed us to evaluate known type-I EC separately (n¼ 627).
The SMC study analysed 687 EC cases (Larsson et al, 2009), the
NHS study analysed 484 EC cases (Wilson et al, 2010), and the
NLCS study evaluated 221 (Hogervorst et al, 2007).
Table 4. ( Continued )
Energy-adjusted acrylamide intake (lg per day)
Quintiles
10 lg
increments Q1 (p14.5) Q2 (14.6–19.5) Q3 (19.6–24.2) Q4 (24.3–32.0) Q5 (32.1–222.4)
Trend test
P-value LRTP-valuea
Menopausal status
Premenopausal
N cases 120 28 25 26 24 17
HR (95% CI)h 0.78 (0.62–0.99) 1.00 (ref) 0.89 (0.48–1.64) 0.91 (0.49–1.71) 0.78 (0.40–1.53) 0.52 (0.24–1.13) 0.09
Perimenopausal 0.01
N cases 120 24 25 32 20 19
HR (95% CI)h 0.88 (0.70–1.12) 1.00 (ref) 0.77 (0.41–1.43) 0.91 (0.49–1.68) 0.67 (0.33–1.36) 0.59 (0.26–1.31) 0.22
Postmenopausali
N cases 387 53 61 67 78 128
HR (95% CI)h 1.07 (0.96–1.18) 1.00 (ref) 1.24 (0.81–1.89) 1.25 (0.81–1.95) 1.09 (0.69–1.72) 1.39 (0.88–2.20) 0.17
Abbreviations: BMI¼body mass index; CI¼ confidence interval; EPIC¼European Prospective Investigation into Cancer and Nutrition; HR¼ hazards ratio; HRT¼hormonal replacement
therapy; LRT¼ likelihood ratio test; OCs¼oral contraceptives.
aAll LRT P-values for effect measure modification are based on the continuous acrylamide intake variable (per 10mg per day).
bStratified by age at recruitment and centre. Adjusted for total energy intake (per 1000 kcal per day), BMI, smoking status, prevalent diabetes, OC use, HRT use, menopause status combined
with age at menopause, parity, and age at menarche.
cStratified by age at recruitment and centre. Adjusted for total energy intake (per 1000 kcal per day), BMI, prevalent diabetes, OC use, HRT use, menopause status combined with age at
menopause, parity, and age at menarche.
dEver smokers: former and current smokers.
eStratified by age at recruitment and centre. Adjusted for total energy intake (per 1000 kcal per day), BMI, smoking status, prevalent diabetes, HRT use, menopause status combined with age at
menopause, parity, and age at menarche.
fStratified by age at recruitment and centre. Adjusted for total energy intake (per 1000 kcal per day), BMI, prevalent diabetes, HRT use, menopause status combined with age at menopause,
parity, and age at menarche.
gStratified by age at recruitment and centre. Adjusted for total energy intake (per 1000 kcal per day), smoking status, prevalent diabetes, OC use, HRT use, menopause status combined with
age at menopause, parity, and age at menarche.
hStratified by age at recruitment and centre. Adjusted for total energy intake (per 1000 kcal per day), BMI, smoking status, prevalent diabetes, OC use, HRT use, parity, and age at menarche.
iIncludes surgical menopause.
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The present study had the following limitations: some food
preparation techniques (e.g., cooking method) that could have
contributed to the variability of total acrylamide intake were not
assessed in all EPIC centres. In addition, the correlation coefficient
between a single 24-h DR in EPIC, and acrylamide intake derived
from food intake questionnaires was low: 0.17 (Ferrari et al, 2013).
This could indicate that a single 24-h DR may not be enough to
accurately estimate the average acrylamide intake. Further, the
EPIC acrylamide estimates might have been influenced by
measurement error; however, all the analyses were adjusted for
energy intake since in EPIC and in other populations, it has been
observed that the validity of acrylamide estimates improved after
energy intake adjustment (Ferrari et al, 2013). Another limitation
of our study is that 718 EC cases were not classified in any of the
EC subtypes; however, as has been previously mentioned, a large
proportion (E80%) of endometrial carcinomas are thought to be
type I (Amant et al, 2005). Finally, it should to be kept in mind that
several subgroups have been examined in this study; thus, some of
the observed results might be due to chance.
In conclusion, the results of the present study indicate that there
were no associations between dietary intake of acrylamide and risk
of overall EC or type-I EC; nevertheless, women with elevated
acrylamide intake (upper quintile median, 44mg per day) who both
never smoked and never used OCs at baseline, were at higher risk
of developing type-I EC relative to women with the lowest intakes.
Additional studies with biomarkers of internal dose of acrylamide
exposure are needed in order to better understand the associations
observed.
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